Efficacy of Turmeric as Adjuvant Therapyin Type 2 Diabetic Patients.

Abstract

It is known that there is a significant interplay of insulin resistance, oxidative stress, dyslipidemia, and inflammation in type 2 diabetes mellitus (T2DM). The study was undertaken to investigate the effect of turmeric as an adjuvant to anti-diabetic therapy. Sixty diabetic subjects on metformin therapy were recruited and randomized into two groups (30 each). Group I received standard metformin treatment while group II was on standard metformin therapy with turmeric (2g) supplements for 4weeks. The biochemical parameters were assessed at the time of recruitment for study and after 4weeks of treatment. Turmeric supplementation in metformin treated type 2 diabetic patient significantly decreased fasting glucose (95±11.4mg/dl, P<0.001) and HbA1c levels (7.4±0.9%, P<0.05). Turmeric administered group showed reduction in lipid peroxidation, MDA (0.51±0.11µmol/l, P<0.05) and enhanced total antioxidant status (511±70µmol/l, P<0.05). Turmeric also exhibited beneficial effects on dyslipidemia LDL cholesterol (113.2±15.3mg/dl, P<0.01), non HDL cholesterol (138.3±12.1mg/dl, P<0.05) and LDL/HDL ratio (3.01±0.61, P<0.01) and reduced inflammatory marker, hsCRP (3.4±2.0mg/dl, P<0.05). Turmeric supplementation as an adjuvant to T2DM on metformin treatment had a beneficial effect on blood glucose, oxidative stress and inflammation.